Valuation: Processa Pharmaceuticals, Inc.

Market Cap 5.66M 5.04M 4.67M 4.25M 8M 538M 8.13M 56.06M 22.1M 281M 21.26M 20.8M 894M P/E 2024
-0.23x
P/E 2025 -0.28x
Enterprise Value 128K 114K 105K 95.65K 180K 12.11M 183K 1.26M 498K 6.32M 479K 468K 20.13M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.18%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Processa Pharmaceuticals, Inc.

1 day+0.60%
1 week+11.18%
Current month+3.05%
1 month-11.05%
3 months-26.84%
6 months-45.48%
Current year-41.32%
1 week 1.5
Extreme 1.5
1.98
1 month 1.04
Extreme 1.041
2.02
Current year 1.04
Extreme 1.041
3.8
1 year 1.04
Extreme 1.041
10.84
3 years 1.04
Extreme 1.041
435
5 years 1.04
Extreme 1.041
4,065
10 years 1.04
Extreme 1.041
125,195.11
Manager TitleAgeSince
Chief Executive Officer 52 07/08/2023
Investor Relations Contact 60 28/03/2011
Chief Administrative Officer 61 03/10/2017
Director TitleAgeSince
Chairman 73 28/03/2011
Chairman 60 15/08/2022
Director/Board Member 56 12/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
08/08/26 Exercice

Chief Executive Officer

3,200 0.1156%
26/07/26 Other

Chief Financial Officer

11,883 0.4293%
26/07/26 Other

Chief Executive Officer

9,384 0.3390%
Change 5-day change 1-year change 3-year change Capi.($)
+0.60%+11.18%-77.91%-99.45% 5.66M
-6.60%-8.56%+49.38%+63.51% 65B
+0.03%+5.56%+9.10%+69.05% 51.2B
-4.09%-0.11%+2.22%+53.15% 51.19B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -1.43%+0.80%+33.18%+74.94% 37.24B
Weighted average by Cap. -2.20%-0.50%+44.25%+96.53%

Financials

2024 2025
Net sales - -
Net income -11.85M -10.55M -9.76M -8.89M -16.73M -1.13B -17.01M -117M -46.22M -587M -44.47M -43.52M -1.87B -13.56M -12.08M -11.17M -10.17M -19.15M -1.29B -19.47M -134M -52.91M -672M -50.9M -49.81M -2.14B
Net Debt -1.12M -996K -921K -838K -1.58M -106M -1.6M -11.06M -4.36M -55.36M -4.19M -4.11M -176M -5.54M -4.93M -4.56M -4.15M -7.82M -526M -7.95M -54.8M -21.6M -274M -20.78M -20.34M -874M
Projected Income Statement - Annual - Processa Pharmaceuticals, Inc.
Logo Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.
Employees
12
Date Price Change Volume
16/10/26 US$1.690 +0.60% 22,058
15/10/26 US$1.680 +4.02% 31,149
14/10/26 US$1.615 -8.76% 46,370
13/10/26 US$1.770 -6.84% 69,180
12/10/26 US$1.900 +25.00% 441,028

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Processa Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. PCSA Stock